Profound Medical Q2 revenue $2.5M (+12% YoY); net loss improves 39% to $9.5M; reiterates FY2026 guidance of $25M

Profound Medical Corp.

Revenue $2.5M, up 12% YoY; $3.1M of TULSA shipments shifted to Q3 due to logistics, resolved.
Net loss $9.5M ($0.26/share) vs $15.7M ($0.52/share) in Q2 2025, a 39% improvement.
Gross margin 78% (up from 73%); operating expenses down 16% to $13.0M.
Reiterates FY2026 revenue guidance of $25.0M (56% YoY growth) and gross margin ≥70%.
TULSA-PRO installed base 84; payer coverage expanded by 18.3M lives; first employer health plans list TULSA.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.